Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DRUG RECALLS FOR 2006

This article was originally published in The Gold Sheet

Executive Summary

...include a surge in Class I-rated actions. Altogether, 27 drug products were recalled that were judged to pose a serious health threat, about two-thirds of which were contaminated. Several contamination-related recalls listed by FDA during the year were associated with FDA inspection findings of significant GMP deviations, including a Class I action involving nine injectable products by a pharmacy compounder. Agency concern about inadequate controls to prevent labeling and packaging mixups prompted a national repacker to recall 174 drug products, swelling the total for the year. FDA is stressing the contamination risks of non-sterile products and is working with industry to upgrade microbial testing practices. [A 12-page tabulation of drug recalls listed in FDA "Enforcement Reports" during 2006 is included.]

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel